ARPA-H Launches Two New Programs
EMBODY: Engineering of Immune Cells Inside the Body
The goal of EMBODY is to radically alter how immune therapies are developed and delivered for life-threatening and chronic conditions by retraining healthy immune cells, and eliminating time, cost and access hurdles.
“By developing agents that target specific immune cell types, essentially providing instructions to cells already active inside your body, we hope to make advanced immunotherapies available close to home for Americans across the country,” said EMBODY Program Manager Daria Fedyukina, Ph.D., in ARPA-H’s recent program announcement.
PRINT (Personalized Regenerative Immunocompetent Nanotechnology Tissue)
PRINT intends to use state-of-the-art bioprinting technology and a regenerative medicine approach to 3D print personalized, on organs that will not require immunosuppressive drugs.
“By starting from multiple different types of cells, we will be creating organs that will be individually matched,” said PRINT Program Manager Ryan Spitler, Ph.D., in ARPA-H’s recent program announcement. “The body will not recognize it as a foreign entity, eliminating the need of immunosuppressive drugs, which has never been done in the history of organ transplantation.”
To learn more about both programs, including how to register for the upcoming Proposers’ Days, visit the EMBODY program page and PRINT program page
- Machine Learning Reassessment of Serum Immune Factors Shows No … – Wiley Online Library
European Journal of Immunology · Volume 55, Issue 7 e70001 European Journal of Immunology. RESEARCH ARTICLE. Open Access. Machine Learning … - The cancer drug, the faked data and the superstar scientist – The Sydney Morning Herald
Mark Smyth was once one of Australia's top scientists. Credit: Some of the world's leading medical journals, including Nature Immunology, have … - Heterozygous loss of MAP4K1 causes immune dysregulation by amplifying T cell responses
To investigate the immunological and functional consequences of HPK1 deficiency in individuals with suspected Inborn Errors of Immunity (IEI). Methods. - Advances in PD-1/PD-L1 pathway inhibitors in the treatment of thyroid cancer – Frontiers
Frontiers in Immunology. doi 10.3389/fimmu.2020.01749. 89,895 views; 387 citations · Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present- … - Bristol Myers Squibb's Leadership Transition: Strategic Continuity or Execution Risks?
The strategic overlap between Massacesi's oncology/immunology focus and BMS's therapeutic priorities is a net positive. However, the transition period …